← Back to Patent Explorer
US5496804A Expired / Lapsed US ⏱️ 0.0 years remaining

Method for treating taxol side-effects with G-CSF

Assignee: United States Department of Health and Human Services
•
Filing: 1994-11-21
•
Granted: 1996-03-05
•
Expires: 2014-11-21
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A method of treating a host using taxol comprising administering granulocyte colony-stimulating factor to the host being treated with taxol. The present inventive method allows for increased levels of taxol to be administered to the host in the treatment of various conditions, particularly with respect to ovarian tumors.

Inventors

  • 👤 Eddie Reed
  • 👤 Elise Kohn
  • 👤 Gisele Sarosy

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-07 12:38
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/193; A61P; A61P39/00

Claims Analysis

Total Claims: 16
Claim 1
Independent Claim 51 words
A method of treating a host being treated with taxol in an amount sufficient to cause a side effect selected from the group consisting of myelosupression, mucositis, and peripheral neuropathy, which method comprises administering to said host granulocyte colony-stimulating factor in an amount effective to alleviate or prevent said side effect.
Claim 2
Independent Claim 51 words
A method of treating a host being treated with taxol in an amount sufficient to cause a side effect selected from the group consisting of myelosupression, mucositis, and peripheral neuropathy, which method comprises administering to said host granulocyte colony-stimulating factor in an amount effective to alleviate or prevent said side effect.
Claim 3
Dependent Claim 24 words
The method of claim 1, wherein said host is being treated with taxol in an amount exceeding about 175 mg/m 2 / 21 days.
Claim 4
Dependent Claim 13 words
A method of claim 1, wherein said side effect is myelosuppression or mucositis.
Claim 5
Dependent Claim 21 words
The method of claim 3, wherein said granulocyte colony-stimulating factor is administered in an amount of at least about 5 μg/kg/day.
Claim 6
Dependent Claim 22 words
The method of claim 4, wherein said granulocyte colony-stimulating factor is administered in an amount of about 10 to about 20 μg/kg/day.
Claim 7
Dependent Claim 34 words
The method of claim 1, wherein said host is being treated with taxol once every three weeks and said granulocyte colony-stimulating factor is administered daily for at least seven days following the taxol treatment.
Claim 8
Dependent Claim 27 words
The method of claim 6 wherein said host is being treated with taxol in an amount of about 200 to about 250 mg/m 2 / 21 days.
Claim 9
Dependent Claim 18 words
The method of claim 1, wherein said host is being treated with taxol to treat a cancerous tumor.
Claim 10
Dependent Claim 16 words
The method of claim 8, wherein said cancerous tumor is a breast, lung or ovarian tumor.
Claim 11
Dependent Claim 13 words
The method of claim 9, wherein said cancerous tumor is an ovarian tumor.
Claim 12
Dependent Claim 24 words
The method of claim 10, wherein said host is being treated with taxol in an amount exceeding about 175 mg/m 2 / 21 days.
Claim 13
Dependent Claim 21 words
The method of claim 11, wherein said granulocyte colony-stimulating factor is administered in an amount of at least about 5 μg/kg/day.
Claim 14
Dependent Claim 22 words
The method of claim 12, wherein said granulocyte colony-stimulating factor is administered in an amount of about 10 to about 20 μg/kg/day.
Claim 15
Dependent Claim 34 words
The method of claim 13, wherein said host is being treated with taxol once every three weeks and said granulocyte colony-stimulating factor is administered daily for at least seven days following the taxol treatment.
Claim 16
Dependent Claim 27 words
The method of claim 14, wherein said host is being treated with taxol in an amount of about 200 to about 250 mg/m 2 / 21 days.

References Cited (Backward Citations)

US4958009A Cited
US4961926A Cited
US4942184A Cited
US5157049A Cited
US5104651A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1999-03-05 1999-09-04 2000-03-05 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2003-03-05 2003-09-04 2004-03-05 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2007-03-05 2007-09-04 2008-03-05 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag